Activity and safety of metformin (MET), Everolimus (EVE) and Octreotide (OCT) in patients (pts) with advanced, well-differentiated (WD) pancreatic neuroendocrine tumors (pNETs). The prospective phase II MetNET-1 trial (NCT02294006). Interim analysis-MedSci.cn - 梅斯（MedSci）

Activity and safety of metformin (MET), Everolimus (EVE) and Octreotide (OCT) in patients (pts) with advanced, well-differentiated (WD) pancreatic neuroendocrine tumors (pNETs). The prospective phase II MetNET-1 trial (NCT02294006). Interim analysis

Pusceddu, S; Prinzi, N; Corti, F; Beninato, T; Milione, M; Centonze, G; Mariani, L; Ljevar, S; Cascella, T; Coppa, J; Di Bartolomeo, M; de Braud, F

JOURNAL OF NEUROENDOCRINOLOGY, 2022; 34 (): 188

科室
- - 订阅+
  - 更多科室
工具
服务